News
04-04-2012, 03:11 AM
Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced positive preclinical results for CTX-0294945 as an adjuvant therapy to the cancer drug Avastin (bevacizumab - Genentech/Roche). The data is presented today in a late breaking poster at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, USA.
More... (http://www.news-medical.net/news/20120404/Positive-preclinical-results-from-Cancer-Therapeutics-CTX-0294945-plus-Avastin-study.aspx)
More... (http://www.news-medical.net/news/20120404/Positive-preclinical-results-from-Cancer-Therapeutics-CTX-0294945-plus-Avastin-study.aspx)